These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11440700)

  • 1. [Symptomatic hyperlactemia in patients infected with the human immunodeficiency virus treated with nucleoside analogs].
    Lozano F; Ramayo E; Corzo JE; Gómez-Mateos J
    Med Clin (Barc); 2001 Jun; 117(1):36. PubMed ID: 11440700
    [No Abstract]   [Full Text] [Related]  

  • 2. Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion.
    Antoniou T; Weisdorf T; Gough K
    CMAJ; 2003 Jan; 168(2):195-8. PubMed ID: 12538549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the nucleoside analogs zidovudine, didanosine, stavudine, and lamivudine on the sense of taste.
    Schiffman SS; Zervakis J; Shaio E; Heald AE
    Nutrition; 1999; 15(11-12):854-9. PubMed ID: 10575660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.
    Giaquinto C; De Romeo A; Giacomet V; Rampon O; Ruga E; Burlina A; De Rossi A; Sturkenboom M; D'Elia R
    AIDS; 2001 May; 15(8):1074-5. PubMed ID: 11399997
    [No Abstract]   [Full Text] [Related]  

  • 5. Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
    Koh MT
    Int J Infect Dis; 2007 Jan; 11(1):85-6. PubMed ID: 16581278
    [No Abstract]   [Full Text] [Related]  

  • 6. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
    Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antiretroviral drugs and pregnancy: apropos of an alert regarding mitochondrial pathology and nucleoside analogs].
    Bavoux F; Loubeyre-Unique C; Blanche S
    Arch Pediatr; 2000 May; 7 Suppl 2():407s-408s. PubMed ID: 10904790
    [No Abstract]   [Full Text] [Related]  

  • 8. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.
    Schweinsburg BC; Taylor MJ; Alhassoon OM; Gonzalez R; Brown GG; Ellis RJ; Letendre S; Videen JS; McCutchan JA; Patterson TL; Grant I;
    J Neurovirol; 2005 Aug; 11(4):356-64. PubMed ID: 16206458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
    Moore RD; Keruly JC; Chaisson RE
    AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity of antiretroviral agents.
    Struble KA; Pratt RD; Gitterman SR
    Am J Med; 1997 May; 102(5B):65-7; discussion 68-9. PubMed ID: 9845500
    [No Abstract]   [Full Text] [Related]  

  • 11. Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy.
    Tseng A; Conly J; Fletcher D; Keystone D; Salit I; Walmsley S
    Clin Infect Dis; 1998 Oct; 27(4):908-9. PubMed ID: 9798060
    [No Abstract]   [Full Text] [Related]  

  • 12. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.
    Divi RL; Leonard SL; Kuo MM; Nagashima K; Thamire C; St Claire MC; Wade NA; Walker VE; Poirier MC
    Environ Mol Mutagen; 2007; 48(3-4):201-9. PubMed ID: 16538687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Painless periungual pyogenic granulomata associated with reverse transcriptase inhibitor therapy in a patient with human immunodeficiency virus infection.
    Williams LH; Fleckman P
    Br J Dermatol; 2007 Jan; 156(1):163-4. PubMed ID: 17199585
    [No Abstract]   [Full Text] [Related]  

  • 14. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
    Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
    Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
    Lonergan JT; Barber RE; Mathews WC
    AIDS; 2003 Nov; 17(17):2495-9. PubMed ID: 14600521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
    Yamamoto Y; Yasuoka A; Yasuoka C; Genka I; Teruya K; Kikuchi Y; Tachikawa N; Oka S
    Jpn J Infect Dis; 2000 Dec; 53(6):244-5. PubMed ID: 11227023
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe skin rash with lamivudine in HIV infected patients: some unusual case reports.
    Modak D; Guha SK
    Indian J Pharmacol; 2013; 45(3):298-300. PubMed ID: 23833379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients].
    Tasias M; Ruiz S; Deig E; Pedrol E
    Enferm Infecc Microbiol Clin; 2011; 29(7):556-7. PubMed ID: 21565428
    [No Abstract]   [Full Text] [Related]  

  • 20. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
    Walker VE; Poirier MC
    Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.